Hemoperfusion with polymyxin B immobilized fibers for urinary albumin excretion in septic patients with trauma.
We investigated whether microalbuminuria/urinary creatinine ratio (MACR) is increased in septic patients with trauma and whether polymyxin B immobilized fiber (PMX-F) treatment decreases MACR. Twelve trauma patients without sepsis, 18 trauma patients with sepsis, and 10 healthy controls were included in this study. The 18 trauma patients with sepsis were randomly assigned to one of two groups, PMX-F treatment or conventional treatment. Urinary microalbumin and creatinine were measured before and after treatment. Plasma endotoxin levels were determined by endospecy test. Hemoperfusion with PMX-F was carried out twice, for 2 hours, at a flow rate of 100 ml/min. MACR increased in the 30 trauma patients (5.2+/-2.2 mg/mmol) in comparison to that in the healthy controls (1.0+/-0.6 mg/mmol, p < 0.01). In the 18 trauma patients with sepsis, MACR after sepsis (16.6+/-4.8 mg/mmol) was significantly greater than that before sepsis (5.5+/-2.3 mg/mmol, p < 0.01). There was a significant correlation between plasma endotoxin levels and MACR in septic trauma patients (p < 0.001). MACR was reduced from 17.0+/-5.0 mg/mmol to 4.2+/-1.5 mg/mmol (p < 0.01) with PMX-F, and plasma endotoxin levels were also reduced from 34.5+/-18.5 pg/ml to 10.8+/-6.6 pg/ml (p < 0.01). Neither MACR nor plasma endotoxin levels were affected by conventional treatment, however. In summary, trauma patients with sepsis appear to show increased MACR, and PMX-F therapy may be effective for attenuating the increase in MACR.
Nakamura
Tsukasa
T
Department of Medicine, Misato Junshin Hospital, Saitama, Japan.
Ushiyama
Chifuyu
C
Suzuki
Yoshimasa
Y
Shoji
Hisataka
H
Shimada
Noriaki
N
Koide
Hikaru
H
D000328:Adult; D000419:Albuminuria / Q000628:therapy* / Q000652:urine; D003404:Creatinine / Q000652:urine; D016228:Endothelial Growth Factors / Q000502:physiology; D004731:Endotoxins / Q000097:blood; D005260:Female; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology; D008222:Lymphokines / Q000502:physiology; D008297:Male; D010976:Platelet Count; D011112:Polymyxin B / Q000009:adverse effects / Q000627:therapeutic use*; D018805:Sepsis / Q000652:urine*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D014947:Wounds and Injuries / Q000652:urine*
D016228:Endothelial Growth Factors; D004731:Endotoxins; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D003404:Creatinine; D011112:Polymyxin B